ArticleFrontiers in medicine2026
Treatment protocol for pneumonia with acute kidney injury: effects of ulinastatin combined with CRRT on inflammatory factors and renal function in patients.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal treatment for patients with pneumonia complicated by acute kidney injury (AKI) remains challenging. This study aims to investigate the clinical efficacy and safety of combining ulinastatin with continuous renal replacement therapy (CRRT) in these patients, thereby providing evidence for clinical treatment planning. Methods: This retrospective study included 100 patients with pneumonia complicated by AKI admitted to our hospital from January 2019 to December 2024. The assignment of patients to treatment groups was based on the regimens recorded in the electronic medical record system, as determined by the treating physicians. Patients were divided into a combination group ( Results: Post-treatment, both groups demonstrated significantly improved levels of inflammatory markers, renal function, pulmonary function, urine pH, and 24-h urine output compared to pre-treatment ( Conclusion: The combination of ulinastatin and CRRT may offer additional benefits over CRRT alone in improving clinical symptoms, inflammatory markers, renal function, and pulmonary function in patients with pneumonia complicated by AKI. However, given the retrospective nature of this study, these findings should be considered preliminary and require confirmation in large-scale, prospective, randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.